Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Shares Outstanding (Weighted Average): 2020-2024

Historic Shares Outstanding (Weighted Average) for ARS Pharmaceuticals (SPRY) over the last 5 years, with Dec 2024 value amounting to $97.2 million.

  • ARS Pharmaceuticals' Shares Outstanding (Weighted Average) rose 1.94% to $98.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $98.8 million, marking a year-over-year increase of 1.94%. This contributed to the annual value of $97.2 million for FY2024, which is 1.24% up from last year.
  • As of FY2024, ARS Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $97.2 million, which was up 1.24% from $96.0 million recorded in FY2023.
  • ARS Pharmaceuticals' 5-year Shares Outstanding (Weighted Average) high stood at $97.2 million for FY2024, and its period low was $28.5 million during FY2020.
  • For the 3-year period, ARS Pharmaceuticals' Shares Outstanding (Weighted Average) averaged around $76.4 million, with its median value being $96.0 million (2023).
  • Data for ARS Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY surged of 166.23% (in 2023) over the last 5 years.
  • ARS Pharmaceuticals' Shares Outstanding (Weighted Average) (Yearly) stood at $28.5 million in 2020, then increased by 23.00% to $35.1 million in 2021, then increased by 2.80% to $36.1 million in 2022, then spiked by 166.23% to $96.0 million in 2023, then increased by 1.24% to $97.2 million in 2024.